Clinical Study on the Safety and Efficacy of QY-1-T in the Treatment of HBV-associated Advanced HCC
Summary
The vast majority of liver cancers have an insidious onset and are often asymptomatic in the early stages, making early diagnosis difficult. Once diagnosed, most liver cancers have reached locally advanced stages or distant metastases, equivalent to Barcelona stage (BCLC) C-D. The tumors progress rapidly and there is a lack of effective treatments. The survival period of cancer patients is generally only 3-6 months. Cellular immunotherapy, including CAR-T and TCR-T, is considered a new hope for the treatment of cancer. The purpose of this study is to explore the safety of QY-1-T (a TCR-T targeting HBV) in the treatment of HBV-related liver cancer, and to preliminarily evaluate the efficacy of QY-1-T in patients with HBV-related advanced liver cancer.
Timeline
- Start
- 2024-01-26
- Primary completion
- 2025-07-31
- Completion
- 2025-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QY-1-T | Cell therapy | 10000 cells/kg | — |
| Subject | QY-1-T | Cell therapy | 100000 cells/kg | — |
| Subject | QY-1-T | Cell therapy | 1e+06 cells/kg | — |
| Subject | QY-1-T | Cell therapy | 5e+06 cells/kg | — |
| Subject | QY-1-T | Cell therapy | 1e+07 cells/kg | — |